ENDRA Life Sciences (NDRA) is a micro-cap developer of TAEUS® thermo-acoustic ultrasound technology for non-invasive liver fat quantification in steatotic liver disease, with its stock showing extreme volatility (52-week range ~$2.96–$9.85) and the company currently exploring strategic alternatives amid persistent losses and limited U.S. commercialization.
Company Overview
Core Technology: TAEUS® (Thermo Acoustic Enhanced UltraSound) – combines radio frequency and ultrasound to measure tissue fat content (steatosis) at point-of-care, ~50x cheaper than MRI, CE-marked in Europe for liver applications but not yet FDA-approved in the U.S.
Focus: Early detection and monitoring of metabolic liver diseases (NAFLD/NASH/SLD) affecting >1–2 billion people globally; potential expansion to tissue temperature monitoring in surgery and other applications.
Headquarters: Ann Arbor, Michigan; ~9 employees (as of latest data).
Status: Pre-revenue or minimal revenue; pursuing metabolic disease detection and GLP-1 drug management uses.
Fact: Incorporated in 2007 as a Delaware corporation; ISO 13485:2016 certified.
Interpretation: Positioned as a potential game-changer for accessible liver diagnostics if regulatory and commercialization hurdles are cleared, but remains high-risk due to development stage.
Company History
2007: Founded/incorporated in Delaware.
2010: Began marketing pre-clinical Nexus 128 system (light-based thermoacoustics + ultrasound); discontinued in 2019.
2013–2016: Shifted focus to TAEUS® platform for clinical use, including liver fat quantification; collaborations (e.g., with CIMTEC in 2017).
2017: NASDAQ listing (NDRA); rang closing bell.
Post-2019: Prioritized TAEUS® liver device; obtained CE mark in Europe; ongoing pursuit of FDA clearance and commercialization.
2025–2026: Raised capital (including potential crypto treasury elements in 2025); initiated strategic alternatives review in March 2026.
Uncertainty/Limitation: Detailed early financials and exact pivot timelines rely on SEC filings; commercialization remains limited as of mid-2026.
Stock Performance
Fact (as of ~July 8–9, 2026 close): Price ≈ $4.76 (down ~3.8% that day); Market cap ≈ $6.0–6.2M; 52-week range: $2.96 – $9.85; Avg. volume ~28K shares; EPS (TTM) ≈ -$8.00; Net loss ongoing (e.g., Q1 2026: -$1.31M).
Metric
Value (Recent)
Notes
Price
$4.76
July 8, 2026 close
Market Cap
~$6.05M
Micro-cap
52-Week High/Low
$9.85 / $2.96
High volatility
YTD Return
~5.08%
vs. S&P 500 ~9.31%
1-Year Return
~42.65% (mixed reports -55% in some sources)
Extreme swings typical
Beta (5Y)
-0.05
Low correlation to market
Interpretation: Highly speculative micro-cap with massive historical drawdowns (e.g., from peaks near $200k adjusted historically) but occasional sharp rallies; analyst target ~$25 (Buy rating from Ascendiant, lowered from $27).
Uncertainty: Returns vary by exact date/source; long-term 5-year performance shows near-total loss in some metrics due to reverse splits/dilution.